Impact of Pantoprazole on Duodeno-Gastro-Esophageal Reflux (DGER)

被引:3
|
作者
Kunsch, S. [1 ]
Neesse, A. [1 ]
Linhart, T. [1 ]
Steinkamp, M. [1 ]
Fensterer, H. [1 ]
Adler, G. [2 ]
Gress, T. M. [1 ]
Ellenrieder, V. [1 ]
机构
[1] Univ Marburg, Dept Gastroenterol Endocrinol & Metab, D-35032 Marburg, Germany
[2] Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany
来源
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2009年 / 47卷 / 03期
关键词
reflux esophagitis; GERD; Bilitec; DGER; bile reflux; GASTROESOPHAGEAL-REFLUX; DUODENOGASTROESOPHAGEAL REFLUX; BARRETTS-ESOPHAGUS; AGONIST BACLOFEN; BILE REFLUX; ACID; PREVALENCE; HEARTBURN; IMPEDANCE; SYMPTOMS;
D O I
10.1055/s-2008-1027865
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Duodeno-gastro-esophageal reflux (DGER) is considered as an independent risk factor for complicated reflux disease (GERD). Patients with Barrett's esophagus have significantly higher levels of DGER than patients with uncomplicated GERD. However, the clinical response to conventional high-dose PPI therapy in patients with uncomplicated GERD and DGER is largely unknown. Methods: 30 patients with uncomplicated GERD and combined pathological reflux (acid and bile) were enrolled in the study. Clinical work-up included evaluation of clinical symptoms, esophageal manometry and upper endoscopy. After 6 8 weeks of treatment with Pantoprazole 80 mg/d pH measurement and Bilitec 2000 were repeated, and the pattern of symptoms was re-evaluated. Results: Under treatment with Pantoprazole 80 mg/d acid reflux was normalised in 28 patients (93%). Similarly the mean percentage of DGER (time with an absorption greater than 0.14) was significantly reduced from 19.6% (+/-13.7) to 5.7% (+/-7.7, p < 0.05). In 15 patients (50%) an elevated DGER persisted under treatment with Pantoprazole (DGER-NR group) whereas in 15 cases (50%) a normalisation could be achieved (DGER-R group). The DGER-NR group had significantly higher levels of bile reflux before (and under) treatment compared to the DGER-R group: 22.9% (9.98%) vs. 15.6% (0.72%), respectively. Overall, the median quality of life index (QLI) improved from 4.78 (+/-0.86) before to 8.04+/-1.84) under therapy. The clinical response under treatment was marikedly reduced in the DGER-NR group compared to the DGER-R group: QLI 7.3 vs. 8.9. Particularly heartburn and nocturnal coughing persisted. Conclusions: Our data confirm that high-dose pantoprazole therapy effectively exerts acid suppression in GERD patients with combined pathological reflux. However, DGER could only normalised in 50% of patients. High levels of DGER at diagnosis enhance the risk of persistent DGER under PPI therapy and are associated with a reduced clinical outcome.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 50 条
  • [1] A human model of duodeno-gastro-esophageal reflux (DGER) in the development of Barrett's esophagus (BE)
    Dresner, SM
    Wayman, J
    Bennett, MK
    Hayes, N
    Griffin, SM
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A410 - A410
  • [2] Duodeno-gastro-esophageal reflux (DGER) in patients with obstructive sleep apnea syndrome (OSAS)
    Almus, E
    Schmalz, O
    Meister, V
    Ellmer, F
    Orth, M
    Monnerjahn, C
    Greving, I
    Schultze-Werninghaus, G
    May, B
    Rasche, K
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A112 - A112
  • [3] Increased Duodeno-Gastro-Esophageal Reflux (DGER) in Symptomatic GERD Patients with a History of Cholecystectomy
    Kunsch, S.
    Neesse, A.
    Huth, J.
    Steinkamp, M.
    Klaus, J.
    Adler, G.
    Gress, T. M.
    Ellenrieder, V.
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2009, 47 (08): : 744 - 748
  • [4] Role of gastric emptying rate in duodeno-gastro-esophageal reflux (DGER) in man.
    Koek, GH
    Lerut, A
    Sifrim, D
    Janssens, J
    Tack, JF
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A1258 - A1258
  • [5] Characteristics of patients with pathological duodeno-gastro-esophageal reflux (DGER) but normal esophageal acid exposure.
    Koek, GH
    Tack, J
    Sifrim, D
    Lerut, T
    Janssens, J
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A217 - A217
  • [6] Causes for duodeno-gastro-esophageal reflux in castroesophageal reflux disease
    Fein, M
    Freys, SM
    Sailer, M
    Maroske, J
    Tigges, H
    Fuchs, K
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : A419 - A419
  • [7] Is duodeno-gastro-esophageal reflux just a bystander of acid reflux?
    Fein, M
    Fuchs, KH
    Freys, SM
    Maroske, J
    Tigges, H
    Thiede, A
    [J]. ZENTRALBLATT FUR CHIRURGIE, 2002, 127 (12): : 1068 - 1072
  • [8] Importance of duodeno-gastro-esophageal reflux in the medical outpatient practice
    Vaezi, MF
    Richter, JE
    [J]. HEPATO-GASTROENTEROLOGY, 1999, 46 (25) : 40 - 47
  • [9] The GABAB agonist baclofen reduces duodeno-gastro-esophageal reflux (DGER) and symptoms in patients with reflux disease refractory to proton pump inhibitor therapy
    Koek, G
    Sifrim, D
    Degreef, T
    Janssens, J
    Tack, J
    [J]. GASTROENTEROLOGY, 2001, 120 (05) : A34 - A34
  • [10] Duodeno-gastro-esophageal reflux: Is the disease better than the CURE
    Nasr, Ayman O.
    Conlon, Susie
    Ghan, Chen
    Ireland, Adrian
    Leen, Eamon
    Bouchier-hayes, David
    Walsh, Thomas N.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A491 - A491